Advertisement

Journal of Neurology

, Volume 255, Issue 2, pp 295–296 | Cite as

Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab

  • G. El Maalouf
  • E. Mitry
  • A. Lacout
  • A. Lièvre
  • P. Rougier
LETTER TO THE EDITORS

Keywords

Vascular Endothelial Growth Factor Bevacizumab Preeclampsia Eclampsia Protein Vascular Endothelial Growth Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hinchey J, Chaves C, Appignani B, et al. (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334(8):494–500PubMedCrossRefGoogle Scholar
  2. 2.
    Nagata M, Maeda M, Tsukahara H, Maier SE, Takeda K (2004) Brain stem hypertensive encephalopathy evaluated by line scan diffusion-weighted imaging. AJNR Am J Neuroradiol 25(5):803–806PubMedGoogle Scholar
  3. 3.
    Hurwitz H, Fehrenbacher L, Novotny W, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342PubMedCrossRefGoogle Scholar
  4. 4.
    Ozcan C, Wong SJ, Hari P (2006) Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354(9):980–982; discussion 980–982PubMedCrossRefGoogle Scholar
  5. 5.
    Glusker P, Recht L, Lane B (2006) Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354(9):980–982; discussion 980–982PubMedCrossRefGoogle Scholar
  6. 6.
    Allen JA, Adlakha A, Bergethon PR (2006) Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 63(10):1475–1478PubMedCrossRefGoogle Scholar
  7. 7.
    Tjoa ML, Levine RJ, Karumanchi SA (2007) Angiogenic factors and preeclampsia. Front Biosci 12:2395–2402PubMedCrossRefGoogle Scholar
  8. 8.
    Levine RJ, Maynard SE, Qian C, et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350(7):672–683PubMedCrossRefGoogle Scholar
  9. 9.
    Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA (2005) Soluble Fmslike tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res 57(5 Pt 2):1R–7RPubMedCrossRefGoogle Scholar
  10. 10.
    Venkatesha S, Toporsian M, Lam C, et al. (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12(6):642–649PubMedCrossRefGoogle Scholar
  11. 11.
    Bdolah Y, Sukhatme VP, Karumanchi SA (2004) Angiogenic imbalance in the pathophysiology of preeclampsia: newer insights. Semin Nephrol 24(6):548–556PubMedCrossRefGoogle Scholar
  12. 12.
    Folkman J (2007) Is angiogenesis an organizing principle in biology and medicine? J Pediatr Surg 42(1):1–11PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2008

Authors and Affiliations

  • G. El Maalouf
    • 1
  • E. Mitry
    • 1
  • A. Lacout
    • 2
  • A. Lièvre
    • 1
  • P. Rougier
    • 1
  1. 1.Dept. of Hepatogastroenterology and digestive oncologyAssistance Publique-Hôpitaux de Paris, Hopital Ambroise PareBoulogneFrance
  2. 2.Dept. of Radiology UniversityVersailles Saint QuentinFrance

Personalised recommendations